Comparative Pharmacology
Head-to-head clinical analysis: CENESTIN versus DIENESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENESTIN versus DIENESTROL.
CENESTIN vs DIENESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and exerting effects on reproductive tissues, bone, cardiovascular system, and CNS.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
0.45 mg orally once daily; titrate up to 1.25 mg once daily based on symptoms. Maximum dose 1.25 mg/day.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life is approximately 10-24 hours for conjugated estrogens; this long half-life allows for once-daily dosing and sustained estrogenic effects.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Primarily renal, with approximately 90% excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile.
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Category C
Category C
Estrogen
Estrogen